Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol

Corynne Marchal; Emeline Orillard; François Calais; Virginie Westeel

doi:10.1002/14651858.CD014907.pub2

Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol

Cochrane Database Syst Rev. 2024 Jul 3;7(7):CD014907. doi: 10.1002/14651858.CD014907.pub2.

Authors

Corynne Marchal¹, Emeline Orillard², François Calais³, Virginie Westeel^{2

4}

Affiliations

¹ Université de Franche-Comté, Besançon, France.
² Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
³ Bibliothèque universitaire de Santé, Université de Franche-Comté, Besançon, France.
⁴ Department of Thoracic Oncology, University Hospital of Besançon, Besançon, France.

Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (ICI) as monotherapy or in combination compared to standard of care for elderly people (≥ 65 years) with non-small cell lung cancer (NSCLC).

MeSH terms

Aged
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / immunology
Carcinoma, Non-Small-Cell Lung* / therapy
Humans
Immune Checkpoint Inhibitors* / therapeutic use
Immunotherapy / methods
Lung Neoplasms* / drug therapy
Lung Neoplasms* / therapy
Randomized Controlled Trials as Topic
Standard of Care
Systematic Reviews as Topic

Substances

Immune Checkpoint Inhibitors